Chardan lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $14 from $16 and keeps a Buy rating on the shares. The firm is adjusting its model to reflect the updated Amtagvi launch guidance, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)
- Iovance Biotherapeutics sees Q2 revenue $86M-$88M, consensus $84.36M
- Iovance Biotherapeutics sees FY26 revenue $350M-$370M, consensus $359.68M
- Unusually active option classes on open May 6th
- Iovance Biotherapeutics (IOVA) Q1 Earnings Cheat Sheet